Teva head Schultz mixes generics with specialty
Executive Summary
Teva is merging its generics and branded ‘specialty’ operations into a single unit with immediate effect, as part of a restructuring led by the Israeli firm’s new president and chief executive officer, Kåre Schultz. Less than a month after he took the role, Schultz said the firm was taking “decisive and immediate action to address external pressures and internal inefficiencies”, after impairment charges wiped out US$6.1 billion of goodwill earlier this year, and the company faces a high debt burden in the wake of buying Actavis.
You may also be interested in...
End Of Schultz Era Looms For Teva
Teva is expecting to have a new CEO by the end of next year, after current leader Kåre Schultz indicated that he was unlikely to renew his contract. The president and chief executive has overseen an eventful and transformative period for the Israeli firm.
Who’s Hired? Stada Makes Moves In Germany And Poland
Stada has appointed general managers for its businesses in Germany and Poland. Meanwhile, US and UK industry associations the AAM and BGMA have announced appointments, Glenmark has added an ex-Teva executive to its board of directors and the MHRA has named a new chair.
Sandoz Prepares For European Natalizumab Launch As Approval Arrives
As it announced the formal European Commission approval of its partnered Polpharma Biologics-developed Tyruko natalizumab biosimilar to Tysabri, Sandoz offered Generics Bulletin a timeframe for its expected launch in Europe.